concert pharamceuticals ppt
DESCRIPTION
about concert pharmaceuticals and its financials by fundamental analysisTRANSCRIPT
NITESH CHHUTANI
DESCRIPTION PIPELINE
PIPELINE TECHNOLOGY FINANCIAL SNAPSHOT (All values in ‘000 and USD)
COMPANY OVERVIEW
• Concert Pharmaceuticals is a clinical stage biotechnology company pioneering the use of deuterium in medicinal chemistry.
• DCE Platform (Deuterated Chemical Entity Platform) to design drug compounds that selectively incorporate deuterium to potentially achieve enhanced clinical safety, tolerability or efficacy in order to improve the outcomes of patients with challenging diseases.
• Targets a broad range of disease areas, including CNS disorders, renal disease, inflammation and cancer.
• By leveraging the large body of knowledge on known drugs, Concert focuses its efforts on valuable opportunities where deuterium modification may provide an important medical benefit.
• Their Innovative approach has already resulted in multiple drug candidates that have advanced into clinical trials. Each of these novel candidates was designed to be improved with deuterium chemistry, and is based on an approved drug, an advanced clinical candidate or a previously studied, biologically active compound
Source: COMPANY OVERVIEW
• DCE Platform consists of the proprietary know-how, techniques and information that the Concert team has developed for nearly a decade.
• Deuterated compounds can have an increased half-life in the body and increased systemic exposure as compared to their corresponding non-deuterated analogs, and these properties can lead to therapeutic benefits such as improved safety, efficacy, tolerability and convenience.
• As a result of Concert’s significant experience in deuterium chemistry and pharmaceutical research and development, the Company is well positioned to efficiently identify compounds that can benefit from deuterium modification and create optimally-designed deuterated product candidates.
• Potential advantages of selective incorporation of deuterium in drug compounds include:• Improved metabolic profile. • Improved oral bioavailability. • Increased half-life.
Source: PIPELINE TECHNOLOGY
• AVP-786(Alzheimer’s agitation)• AVP-786(Major Depressive Disorder)• CTP-499(Diabetic nephropathy)• CTP-354(Associated with SCI & MS)• JZP-386(Narcolepsy)• CTP-730 (Inflammatory Diseases)• D-IVACAFTOR (Cystic Fibrosis)
Source: PRODUCT PIPELINE
Profit and Loss 2011 2012 2013 2014
Revenues 19,467 12,849 25,408 8,576
Operating Profit (10,443) (17,742) (3,407) (28,905)
Net Profit (10,417) (19,576) (5,053) (30,006)
Balance sheet
Total Assets 49,403 33,129 39,773 84,454
Stock Holders Equity (86,718) (106,687) (112,104) 54,825
Total Debt 8,380 20,644 15,500 7,101
Cash flow
Net Cash Flow-Operating (18,085) (26,427) 13,018 (29,760)
Net cash flow investing 22,901 (1,200) (3,637) (44,452)
Net Cash Flows-Financing 6,985 12,168 (7,233) 77,970
MANAGEMENT TEAM HISTORY
SHARE HOLDING PATTERN PATENTS
SNAPSHOT
Total Pharmaceutical Sales 2014USD 32.3 bn
NAME QUALIFICATION DESIGNATION PREVIOUS DESIGNATION
Roger Tung, Ph.D. B.A. in Chemistry,Ph.D. in Medicinal Chemistry
Co-Founder, President and CEO
Founding Scientist, Vice President of Drug Discovery, at Vertex
James Cassella, Ph.D
Ph.D. in Physiological Psychology ,B.A. in Psychology
Chief Development Officer Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc.
Nancy Stuart B.S. ,M.B.A. Chief Operating Officer Business Perations And Business Development Positions At Amgen Inc.
Ryan Daws B.S. in Finance and Organizational Management International M.B.A.
Chief Financial Officer An Independent consultant
Robert Silverman, J.D., Ph.D
J.D., Ph.D. in organic chemistry a B.A.
Senior Vice President and General Counsel
Legal related roles at Millennium Pharmaceuticals, Inc.
13%
11%
7%
6%
5%
59%
Share Holding Pattern
BVF INC/IL
SENZAR ASSET MAN-AGEMENT, LLC
FRANKLIN RESOURCES INC
RA CAPITAL MANAGEMENT, LLC
POINT72 ASSET MAN-AGEMENT, L.P.
OTHERS
Source: MANAGEMENT TEAM
Source: SHARE HOLDING
Headquarters: Lexington, MAFounded: April 2006Nasdaq Listed: CNCEEmployees: 57Strategic Collaborators:Avanir PharmaceuticalsCelgene CorporationJazz PharmaceuticalsProprietary Technology:DCE Platform(Deuterium Chemical Entity Platform)Issued U.S. Patents: 67CEO: Roger Tung, Ph.D.Chairman of the Board: Richard Aldrich
Source: ABOUT CONCERT
DATE OF ISSUE
PATENT NO. PATENT NAME INVENTORS
FEB 10 ,2015
US8952016Β2 Substituted xanthine derivatives Roger D. Tung, Lexington, ΜΑ (US)
NOV 11 ,2014
US 8883843 B2 Substituted isoindoline-l,3-dioneDerivatives
Julie F. Liu, Lexington, MA (US)
JUNE 24 ,2014
US 8759383 B2 Inhibitors of cholesterol ester transfer protein
Roger Tung, Lexington, MA
MAR 26 ,2013
US 8404737 B2 Substituted isoindoline-1,3-dioneDerivatives
Julie F. Liu, Lexington, MA (US)
FEB 28,2012
US 8124646 B2 Substituted isoindoline-1,3-dioneDerivatives
Julie F. Liu, Lexington, MA (US)
Source :PATENTS
PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3
AVP-786(Alzheimer’s agitation)
AVP-786(Major Depressive Disorder)
CTP-499(Diabetic nephropathy)
CTP-354(Associated with SCI & MS)
JZP-386(Narcolepsy)
CTP-730 (Inflammatory Diseases)
D-IVACAFTOR (Cystic Fibrosis)
Source: PIPELINE
PIPELINE
PRICE CHART COLLABORATIONS
REVENUE TREND
OVERVIEW
Total Pharmaceutical Sales 2014USD 32.3 bn
DATE PLACE COLLABORATED WITH ABOUT
MAY 6 ,2013
Lexington CELGENE CORPORATION Strategic Collaboration with Celgene Corporation toDevelop Deuterium-Modified Compounds
FEB 23 ,2013
Dublin & Lexington JAZZ PHARMACEUTICALS Worldwide LicensingAgreement to Develop and Commercialize Deuterium-Modified Sodium Oxybate
MAR 5 ,2012
Lexington,New York FAST FORWARD LLC Collaboration to Advance NovelTreatment for Spasticity and Pain in Multiple Sclerosis
FEB 29 ,2012
Aliso Viejo, Lexington
AVANIR PHARMACEUTICALS License Agreement toDevelop and Commercialize Deuterium-Modified Dextromethorphan for Disorders of theNervous System
FEB 2 ,2011
Lexington WALTER REED ARMY INSTITUTE OF RESEARCH
Evaluate Neuroprotective Drug Compound;Advances Concert’s R&D for Novel Drugs to Treat Seizure-Generating Diseases
JUNE 2 ,2009
Lexington GLAXOSMITHKLINE Alliance to Develop Novel DeuteriumModified Drugs
2/13/2
014
2/28/2
014
3/15/2
014
3/30/2
014
4/14/2
014
4/29/2
014
5/14/2
014
5/29/2
014
6/13/2
014
6/28/2
014
7/13/2
014
7/28/2
014
8/12/2
014
8/27/2
014
9/11/2
014
9/26/2
014
10/11/2
014
10/26/2
014
11/10/2
014
11/25/2
014
12/10/2
014
12/25/2
01402468
10121416
2011 2012 2013 20140
5,000
10,000
15,000
20,000
25,000
30,000
Revenue
YEARS
REVE
NUE
Source: FINANCIALS AND FILINGS
Source: COLLABORATIONS
POSITIVE NEWS
0
2
4
6
8
10
12
14
16
Achieves $2 Million Milestone for AVP-786 Under AvanirPharmaceuticals Collaboration
FDA Lifts Partial Clinical Hold for CTP-354, A NovelDrug Candidate for Spasticity
Positive Data from Multiple Dose Phase 1 Clinical Trial ofCTP-354, Lead Candidate for the Treatment of Spasticity
INCOME STATEMENT CASH FLOW STATEMENT
BALANCE SHEET RATIOS
FINANCIAL STATEMENTS(All values in ‘000 and USD except ratios)
Total Pharmaceutical Sales 2014USD 32.3 bn
http://www.nasdaq.com/symbol/cnce/ownership-summaryRATIOS 2011 2012 2013 2014
ROE-16% 13% -4% 11%
ROCE30% 50% 8% -93%
EPS-8.12 -15.18 -3.91 -1.89
ROA56% -81% 21% 14%
ROIC-70% -76% -50% 953%
Gross Profit Margin100% 100% 100% 100%
Asset turnover Ratio0.8 0.8 1.3 0.2
Book Value-67.6 -82.7 -86.8 3.5
CASH FLOW STATEMENT 2011 2012 2013 2014
Net Income (11,320) (20,444) (6,056) (31,699)
Cash Flows Operating activities
Net Cash Flow Operating(18,085) (26,427) 13,018 (29,760)
Cash Flows Investing Activities
Net Cash Flows Investing22,901 (1,200) (3,637) (44,452)
Cash Flows Financing Activities
Net Cash Flows Financing 6,985 12,168 (7,233) 77,970
Net Cash Flow 11,801 (15,459) 2,148 3,758
BALANCE SHEET 2011 2012 2013 2014
Cash and Cash Equivalents 22,949 7,490 9,638 13,396
Investments 19,705 20,067 23,039 65,836
Total Current Assets 44,135 28,850 34,045 81,720
Fixed Assets 4,438 3,454 2,473 2,284
Other Assets 830 825 3,255 450
Total Assets 49,403 33,129 39,773 84,454
Current Liabilities
Total Liabilities 24,661 27,968 39,633 29,629
Other Equity 9 4 4 (14)
Total Equity (86,718) (106,687) (112,104) 54,825
Total Liabilities & Equity (62,057) (78,719) (72,471) 84,454
INCOME STATEMENT 2011 2012 2013 2014
License and research and development revenue 13967 11349 23408 6576
Milestone revenue 5,500 1,500 2,000 2,000
Total revenue 19,467 12,849 25,408 8,576
Operating expenses:
Research and development 22,864 23,629 21,207 26,672
General and administrative 7,046 6,962 7,608 10,809
Loss from operations (10,443) (17,742) (3,407) (28,905)
Investment income 44 22 21 49
Interest and other expense (18) (1,856) (1,667) (1,150)
Net loss (10,417) (19,576) (5,053) (30,006)
Source: FINANCIALS AND FILINGS
Source: FINANCIALS AND FILINGS
Source: FINANCIALS AND FILINGS